GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Jun 18, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jun 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, sec-filing, foreign-private-issuer
TL;DR
GSK is buying back its own stock.
AI Summary
GSK plc announced on June 18, 2025, that it purchased a number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing is a report of foreign private issuer for the month of June 2025.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of share repurchases and does not indicate any immediate material risks.
Key Players & Entities
- GSK plc (company) — Registrant
- Merrill Lynch International (company) — Corporate stockbroker
- June 2025 (date) — Reporting period
- 001-15170 (other) — Commission File Number
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K filing is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, for the month of June 2025, specifically detailing a transaction in own shares.
Who is acting as GSK's corporate stockbroker for this transaction?
Merrill Lynch International is acting as GSK's corporate stockbroker for the purchase of its own shares.
What type of shares did GSK purchase?
GSK purchased its own ordinary shares of 31¼ pence each.
What is the filing date and period of report for this document?
The filing date is June 18, 2025, and the conformed period of report is also June 18, 2025.
Does GSK file annual reports under Form 20-F or Form 40-F?
GSK indicates by check mark that it files annual reports under cover of Form 20-F.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 18, 2025 regarding GSK plc (GLAXF).